Comparative performance of uncoated, self-expanding metal biliary stents of different designs in 2 diameters: final results of an international multicenter, randomized, controlled trial - 23/08/11
Portland, Maine, Springfield, Massachusetts, Denver, Colorado, Chicago, Illinois, Charleston, South Carolina, Pittsburgh, Pennsylvania, Indianapolis, Indiana, USA, Toronto, Ontario, Canada, Düsseldorf, Germany
Abstract |
Background |
The Wallstent has remained the industry standard for biliary self-expanding metal stents (SEMSs). Recently, stents of differing designs, compositions, and diameters have been developed.
Objective |
To compare the new nitinol 6-mm and 10-mm Zilver stents with the 10-mm stainless steel Wallstent and determine the mechanism of obstruction.
Design |
Randomized, prospective, controlled study.
Setting |
Nine centers experienced in SEMS placement during ERCP.
Patients |
A total of 241 patients presenting between September 2003 and December 2005 with unresectable malignant biliary strictures at least 2 cm distal to the bifurcation.
Main Outcome Measurement |
Stent occlusions requiring reintervention and death.
Results |
At interim analysis, a significant increase in occlusions was noted in the 6-mm Zilver group at the P = .04 level, resulting in arm closure but continued follow-up. Final study arms were 64, 88, and 89 patients receiving a 6-mm Zilver, 10-mm Zilver, and 10-mm Wallstent, respectively. Stent occlusions occurred in 25 (39.1%) of the patients in the 6-mm Zilver arm, 21 (23.9%) of the patients in the 10-mm Zilver arm, and 19 (21.4%) of the patients in the 10-mm Wallstent arm (P = .02). The mean number of days of stent patency were 142.9, 185.8, and 186.7, respectively (P = .057). No differences were noted in secondary endpoints, and the study was ended at the 95% censored study endpoints. Biopsy specimens of ingrowth occlusive tissue revealed that 56% were caused by benign epithelial hyperplasia.
Conclusions |
SEMS occlusions were much more frequent with a 6-mm diameter SEMS and equivalent in the two 10-mm arms despite major differences in stent design, material, and expansion, suggesting that diameter is the critical feature. Malignant tumor ingrowth produced only a minority of the documented occlusions.
Le texte complet de cet article est disponible en PDF.Abbreviation : FDA, SEMS
Plan
| DISCLOSURE: The following authors disclosed financial relationships relevant to this publication: D. A. Howell: Cook Medical: royalty on unrelated product, grant, research support, speaking and teaching; Boston Scientific: grant/research support. D. J. Desilets: Cook Medical: grant/research support; royalty on patent held/filed. R. J. Shah: Boston Scientific: speaking/teaching; Wilson–Cook Medical: grant/research support; Boston Scientific: grant/research support, consulting fee. R. H. Hawes: Boston Scientific: consulting fee. P. B. Cotton: Cook: royalty on patent held/filed; Boston Scientific: grant/research support. A. A. Slivka: Boston Scientific: consulting fee, speaking/teaching; Wilson–Cook Medical: consulting fee, speaking/teaching. S. Sherman: Boston Scientific: consulting fee, speaking/teaching; Cook: consulting fee, speaking/teaching. This study was supported with institutional grants to each center from Cook Medical. All other authors disclosed no financial relationships relevant to this publication. |
|
| See CME section; p. 537. |
|
| Presented at: Digestive Disease Week, May 2008, San Diego, California (Gastrointest Endosc 2009;69:A93). |
|
| If you would like to chat with an author of this article, you may contact him at howeld@mmc.org. |
Vol 70 - N° 3
P. 445-453 - septembre 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
